Showing results (211-220 of 900) with videos related to

Sort By:
Pageof 90
Acta Haematologica|April 15, 2020
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid LeukemiasAbhishek Maiti, Miguel J Franquiz, Farhad Ravandi, et al.
American Journal of Hematology|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1Nicholas J Short, Elias Jabbour, Walid Macaron, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Blood|August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatmentGhayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood Cancer Journal|May 6, 2020
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBachar Samra, Guillaume Richard-Carpentier, Tapan M Kadia, et al.
Cancer|October 12, 2018
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvageElias Jabbour, Koji Sasaki, Farhad Ravandi, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
The Lancet. Haematology|September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trialNicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
Blood Advances|November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaNicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
Pageof 90